By strengthening the company's fibrotic disease development pipeline, Bridge will enhance its strategic focus on the development of comprehensive treatment solutions for idiopathic pulmonary fibrosis (IPF)
The company plans to file its NDA in China and MAA in the EU in 2022, making Hansizhuang potentially to be the world's first PD-1 inhibitor for the first-line treatment of SCLC
A novel second-generation approach to achieve a safe, durable, and stable transgene expression to overcome the challenges of factor VIII replacement therapies
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
Casimir further differentiates Emmes’ industry-leading rare disease research capabilities
Nulibry is approved by the U.S. Food and Drug Administration (USFDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening paediatric genetic disorder
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
With ValGenesis VLMS, change control driven validation activities are reduced from weeks to mere hours, and the company gains faster access to detailed metrics that help reduce costs and cycle time
New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong
Sanofi unveiled a new bold and unifying corporate brand that supports the modernization and transformation the company launched in December 2019
Subscribe To Our Newsletter & Stay Updated
